A randomized phase II trial to investigate optimal duration (4 month versus 6 month) of preoperative endocrine therapy
Not Applicable
- Conditions
- breast cancer
- Registration Number
- JPRN-UMIN000005668
- Lead Sponsor
- ational Cancer Center Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1) History of chemotherapy or endocrine therapy for breast cancer. 2) Receiving any drugs that may affect the sex hormone status.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method